Use of Heliox Associated With PEEP in Patients With Asthma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Pernambuco
-
Recife, Pernambuco, Brazil
- Hospital das Clínicas
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with clinical diagnosis of persistent asthma
- FEV1 <60% predicted more than one year
- Reversibility of bronchial obstruction after administration of bronchodilators at least 10% in FEV1 on spirometry.
Exclusion Criteria:
- patients unable to understand or perform the spirometric maneuver or failed to keep in proper positioning to obtain the scintigraphic images
- History of smoking over the past three years associated with a consumption greater than 100 cigarettes per year or who had history of smoking increased 10 years
- pulmonary comorbidities such as COPD, bronchiectasis and tuberculosis sequelae
- Pregnancy and any contraindication to the use of PEP, such as active hemoptysis, sinusitis, surgery or facial trauma, oral or injury, epistaxis, esophageal surgery and nausea.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Heliox + PEP (Group 1)
|
For the nebulization with heliox was used radioaerosol a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France).
This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to the PEP.
PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch.
The nebulizer was fed by a flow of 11 l / min of heliox for the heliox group according to the protocol of Hess et al.
When powered by heliox mixture, the flow was adjusted flowmeter suitable for this mixture.
|
|
EXPERIMENTAL: Oxygen+PEP(Group 2)
|
For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France).
This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to PEP (Figure 2).
PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch.
The nebulizer was fed by a stream of 8 l / min oxygen.
|
|
EXPERIMENTAL: Heliox ( Group 3)
|
For the nebulization with heliox we used a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France).
We used a PEP valve without resistance.
|
|
ACTIVE_COMPARATOR: Oxygen (Group 4)
|
For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France).
We used a PEP valve without resistance.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pulmonary deposition radioaerosol
Time Frame: 6 mouths
|
For inhalation lung scintigraphy, was administered an average dose of acid dietilnotriaminopentaacético labeled with Technetium (DTPA - 99mTc) from 25 to 10 mCi associated bromide drops and 20 drops of Fenoterol bromide ipatropium diluted to a total of up to 3 ml saline 0.9%.
|
6 mouths
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pulmonary Function
Time Frame: The patient was the pulmonary function test before and after intervention.
|
To obtain spirometric values and CI were asked the patients to perform three maneuvers.
Spirometry were analyzed FEV1, PEF and forced vital capacity (FVC), considering the percentage of predicted as the best value recorded in accordance with American Thoracic Society.
For CI, this correction was performed by body mass index (BMI) and weight.
|
The patient was the pulmonary function test before and after intervention.
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Piva JP, Menna Barreto SS, Zelmanovitz F, Amantea S, Cox P. Heliox versus oxygen for nebulized aerosol therapy in children with lower airway obstruction. Pediatr Crit Care Med. 2002 Jan;3(1):6-10. doi: 10.1097/00130478-200201000-00002.
- Hess DR, Acosta FL, Ritz RH, Kacmarek RM, Camargo CA Jr. The effect of heliox on nebulizer function using a beta-agonist bronchodilator. Chest. 1999 Jan;115(1):184-9. doi: 10.1378/chest.115.1.184.
- Alcoforado L, Brandao S, Rattes C, Brandao D, Lima V, Ferreira Lima G, Fink JB, Dornelas de Andrade A. Evaluation of lung function and deposition of aerosolized bronchodilators carried by heliox associated with positive expiratory pressure in stable asthmatics: a randomized clinical trial. Respir Med. 2013 Aug;107(8):1178-85. doi: 10.1016/j.rmed.2013.03.020. Epub 2013 May 9.
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 31012010
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.